# Ryan Drant

> Ryan Drant is a Series B investor at Questa Capital Management backing Health Care. See 42 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Questa Capital Management](https://shizune.co/investors/profile/questa-capital-management)
- Location: Washington, United States
- Total investments: 42
- Last investment: Apr 2026
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ryan-drant-a37b53
- X (Twitter): http://twitter.com/RDeeee
- Website: https://x.com/RDeeee

Ryan Drant is a Series B investor at Questa Capital Management in Washington focused on Health Care and Medical Device. Ryan joined NEA in 1996, and became a General Partner in 2004. He specializes in healthcare investments in the medical device, healthcare information technology and specialty pharma sectors. Present board memberships include BENU, Carticept Medical, Concentric Medical, CVIngenuity, DSI Renal, ExploraMed III, Intrinsic Therapeutics, Neotract,PatientKeeper, Simplex Healthcare, Solace Therapeutics, Spine Wave, TriVascular, Ulthera and Vibrynt. Ryan also serves on the board of the Medical Device Manufacturers Association.Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Esprit Pharma (acquired by Allergan), FoxHollow Technologies (acquired by EV3, now Covidien), Provation Medical (acquired by Wolters Kluwer), and Proxima Therapeutics (acquired by Cytyc Corporation, now Hologic), and Ryan co-led NEA’s investment in Xcel Pharmaceuticals (acquired by Valeant Pharmaceuticals, Inc.). Prior to joining NEA, Ryan was with the Health Care Investment Banking Group of Alex. Brown & Sons in San Francisco. Previously, he worked in the San Francisco office of Arthur Andersen & Co. Ryan received a BA from Stanford University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 17 | 40% |
| Medical Device | 11 | 26% |
| Medical | 6 | 14% |
| mHealth | 3 | 7% |
| Software | 2 | 5% |

31 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 10 | 24% |
| Series C | 8 | 19% |
| Series A | 5 | 12% |
| Series D | 4 | 10% |
| Funding Round | 4 | 10% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 38% |
| Canada | 2 | 5% |
| United Kingdom | 1 | 2% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Calyxo | Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones, a common and painful condition that consumes vast amounts of healthcare resources today. Founded in 2016, Calyxo is led by executives and investors with a strong track record of commercializing paradigm-shifting solutions in thefield of urology. Our team features some of the most talented, high-achieving and brightest minds in the medical device industry who are compelled by a desire to make a difference in kidney stone care. We are proud of our collaborative, diverse, fun and dynamic culture. | $40M | Series F | Apr 14, 2026 |  |
| Bicycle Health | Bicycle Health is a virtual addiction medicine clinic that helps treat opioid dependence or use disorder. Addiction medicine specialists on the Bicycle Health platform will treat patients and works with the patient's insurance to get reimbursed for their services. The telemedicine-based company uses an interesting model to become anaddiction medicine resource that physicians leverage for their patients while maintaining and strengthening their relationship with their patients.Ankit Gupta established it in San Francisco, California in 2017. | $16.5M |  | Jan 29, 2025 |  |
| Aerin Medical | Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing. Its device utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion, enabling patients suffering from nasal breathing disorders to open their nasal airway quickly, safely, andeffectively. | $32.5M | Private Equity | Jan 13, 2025 |  |
| Aerin Medical | Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing. Its device utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion, enabling patients suffering from nasal breathing disorders to open their nasal airway quickly, safely, andeffectively. |  |  | Jan 13, 2025 |  |
| Aerin Medical | Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing. Its device utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion, enabling patients suffering from nasal breathing disorders to open their nasal airway quickly, safely, andeffectively. | $32.5M |  | Jan 13, 2025 |  |
| Ossio | OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents abreakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind.Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now. | $27.6M | Series D | Dec 02, 2024 |  |
| ACTO | ACTO is an omnichannel education platform for life sciences companies. ACTO is an AI-powered SaaS platform built for life sciences that uses mobile experiences and agency partnerships to give learners all the tools they need in one intuitive cross-platform app, and give leaders powerful admin tools with engagement data in one command center. | $7.4M | Venture - Series Unknown | Sep 12, 2024 |  |
| Eko Health | Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detectearlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com. | $41M | Series D | Jun 05, 2024 |  |
| PocketHealth | PocketHealth is a better way to instantly receive and share sensitive medical imaging information. PocketHealth’s platform allows patients to share imaging records electronically with patients. | $33M | Series B | Mar 20, 2024 |  |
| Avive Solutions | Avive Solutions develops a next-generation Automated External Defibrillator (AED) and software solutions. Avive's AED enables anyone to positively impact the outcome of a Sudden Cardiac Arrest (SCA) rescue by building a more robust solution that addresses the problem of SCA in its entirety. The AED will remove barriers to respond to a SCAscenario. It will be easy to purchase, easy to access in an emergency, easy to keep maintained, and most importantly easy to use effectively when it matters most.Avive Solutions is headquartered in San Francisco, California. | $56.5M | Series B | Feb 14, 2024 |  |

10 of 42 investments shown.

## Co-investors
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 7 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 5 deals together
- [Echo Health Ventures](https://shizune.co/investors/profile/echo-health-ventures-llc) — VC Fund, 4 deals together
- [Global Ventures](https://shizune.co/investors/profile/global-ventures) — VC Fund, 4 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 4 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 3 deals together

## About Questa Capital Management

VC Fund · San Francisco, United States

Questa Capital Management is a healthcare venture growth equity firm investing in breakout growth companies.

5 contacts available at Questa Capital Management.

| Name | Title | Profile |
| --- | --- | --- |
| Aabed Meer | Partner | https://shizune.co/investors/profile/aabed-meer |
| Bradley Sloan | Managing Partner | https://shizune.co/investors/profile/brad-sloan |
| Bradley Sloan | Managing Partner | https://shizune.co/investors/profile/bradley-sloan |
| Brian L. Butler | Vice President | https://shizune.co/investors/profile/brian-l-butler |
| Ryan Drant | Founder & Managing Partner | https://shizune.co/investors/profile/ryan-drant |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ryan Drant invest in?

Ryan Drant invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series C stage. Most of the 42 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ryan Drant last invest?

The most recent investment recorded for Ryan Drant closed in Apr 2026. Shizune tracks 42 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co